MedTrace Logo

Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE

NCT03673943 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2022-12-22

Study results available
· View outcomes & findings →

Summary

This is an open-label, single-dose, single-arm, single-center imaging study using DOTATATE peptide, labelled with the 64Cu tracer.

Conditions

Interventions

DRUG

64Cu-DOTATATE

Detection of somatostatin positive lesions in NET

Sponsors & Collaborators

  • Radiomedix, Inc.

    lead INDUSTRY

Principal Investigators

  • Ebrahim S Delpassand, MD · Radiomedix, Inc.

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-08-23
Primary Completion
2019-03-23
Completion
2019-08-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03673943 on ClinicalTrials.gov